Fred A. Middleton net worth and biography

Fred Middleton Biography and Net Worth

Director of Chimerix

Mr. Middleton has served as one of our directors since March 2018. He currently serves as a Managing Director of Sanderling Ventures, where he has worked for over 30 years as an investor, management team member and as a director in over 25 new biomedical ventures built in Sanderling’s venture investment portfolios since 1988. During his time at Sanderling, Mr. Middleton served as Vice Chairman and Chief Business Officer of Altor Biosciences, where he helped raise over $100M for clinical trials development and negotiated its subsequent acquisition by immunityBio, Inc. Mr. Middleton was an investor in Regeneron Pharmaceuticals and served as a board member and as the company’s CFO during its initial public offering in 1991. Earlier in his career, Mr. Middleton served as the third original member of the Genentech management team as its Chief Financial Officer from 1978-2004, completing its IPO in 1980. Mr. Middleton currently serves on the Boards of Directors for Viacyte, Inc., Calcimedica, Inc., and TheraVida, Inc., all privately held companies. Mr. Middleton holds a B.S. in chemistry from the Massachusetts Institute of Technology and an MBA with Distinction from the Harvard Business School.

What is Fred A. Middleton's net worth?: The estimated net worth of Fred A. Middleton is at least $857,750.06 as of January 23rd, 2024. Mr. Middleton owns 946,744 shares of Chimerix stock worth more than $857,750 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Middleton may own. Learn More about Fred A. Middleton's net worth.
How do I contact Fred A. Middleton?: The corporate mailing address for Mr. Middleton and other Chimerix executives is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. Chimerix can also be reached via phone at (919) 806-1074 and via email at [email protected]. Learn More on Fred A. Middleton's contact information.
Has Fred A. Middleton been buying or selling shares of Chimerix?: Fred A. Middleton has not been actively trading shares of Chimerix over the course of the past ninety days. Most recently, on Friday, November 10th, Fred A. Middleton bought 2,705 shares of Chimerix stock. The stock was acquired at an average cost of $0.92 per share, with a total value of $2,488.60. Following the completion of the transaction, the director now directly owns 82,705 shares of the company's stock, valued at $76,088.60. Learn More on Fred A. Middleton's trading history.
Who are Chimerix's active insiders?: Chimerix's insider roster includes David Jakeman (Insider), Robert Meyer (Director), and Fred Middleton (Director). Learn More on Chimerix's active insiders.
Are insiders buying or selling shares of Chimerix?: In the last twelve months, Chimerix insiders bought shares 5 times. They purchased a total of 101,155 shares worth more than $110,981.60. In the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 9,954 shares worth more than $10,171.66. The most recent insider tranaction occured on February, 14th when CEO Michael T Andriole sold 1,744 shares worth more than $1,813.76. Insiders at Chimerix own 10.0% of the company. Learn More about insider trades at Chimerix.
Information on this page was last updated on 2/14/2024.

Fred A. Middleton Insider Trading History at Chimerix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/10/2023	Buy	2,705	$0.92	$2,488.60	82,705
9/25/2023	Buy	20,000	$0.98	$19,600.00	80,000
3/28/2023	Buy	20,000	$1.21	$24,200.00	60,000
9/29/2022	Buy	20,000	$1.86	$37,200.00	40,000
6/28/2021	Buy	6,950	$7.83	$54,418.50	200,573
6/25/2021	Buy	3,050	$7.78	$23,729.00	200,573
3/12/2020	Buy	50,000	$1.40	$70,000.00	197,523
11/13/2019	Buy	30,000	$1.82	$54,600.00	117,523
11/11/2019	Buy	20,000	$1.66	$33,200.00	117,523
5/10/2019	Buy	30,000	$2.92	$87,600.00	97,523

Fred A. Middleton Buying and Selling Activity at Chimerix

Chimerix Company Overview

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Today's Range

Now: $0.91

$0.90

$0.93

50 Day Range

MA: $1.08

$0.88

$1.26

2 Week Range

Now: $0.91

$0.88

$1.57

Volume

88,198 shs

Average Volume

293,645 shs

Market Capitalization

$80.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…